ArticleApplied biochemistry and biotechnology2026
miRNA-1231 Regulated EGFR Signaling: A Potential Therapeutic Target for Hepatocellular Carcinoma.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver Cancer is the sixth leading cause of morbidity and mortality worldwide. Effective treatment for HCC is challenging and heavily depends on early diagnosis. There is urgent need to identify a potent therapeutic target for HCC. Among various signaling pathways EGFR signaling cascade plays a crucial role in cancer cell growth and proliferation. Therefore, the inhibition of this pathway would be an effective treatment strategy for HCC. To investigate the inhibitory role of miRNA-1231 in EGFR pathway gene expression analysis was performed. Immunohistochemistry was also done for EGFR protein expressions analysis in HCC tissues. Interaction of EGFR with other genes was also analyzed using STRING database. Furthermore, molecular docking was conducted to evaluate the interaction between miRNA and EGFR mRNA. In this study, EGFR, AKT, mTOR, BCL2 and MDM2 genes were found to be significantly upregulated in HCC tissues while FOXO3, BIM and miRNA-1231 were downregulated (*p < 0.05). Immunohistochemical staining also showed positive expressions of EGFR protein in HCC tissues as compared to non-cancerous tissues. PPI network analysis resulted in the generation of network showing strong interactions of EGFR with other genes. Additionally, Survival analysis of miRNA-1231 showed that the low expression of miRNA-1231 is related with poor outcome of HCC. Molecular docking analysis also indicated that there is strong interaction between miRNA-1231 and EGFR mRNA. We investigated that miRNA-1231 regulated EGFR pathway plays a major role in initiation and progression of HCC. Therefore, this data concluded that miRNA-1231 could be a potential prognostic marker as well as therapeutic target for HCC.
Indexed as
Identifiers
41627674What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.